Cytori Therapeutics, Inc.
3020 Callan Road
San Diego,
CA 92121
United States - Map
Phone: 858-458-0900
Fax: 858-458-0994
Web Site: http://www.cytoritx.com
| Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system. The company was founded in 1996 and is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Christopher J. Calhoun , 44
Co-Founder, Vice Chairman, Chief Exec. Officer, Sec. and Member of Exec. Committee |
$
420.00K |
$
471.00K | Dr. Marc H. Hedrick M.D., 47
Pres, Chief Scientific Officer, Medical Director |
$
384.00K |
$
0 | Mr. Mark E. Saad , 40
Chief Financial Officer |
$
350.00K |
$
0 | Mr. Seijiro N. Shirahama , 56
Pres of Asia Pacific |
$
260.00K |
$
0 | Mr. Bruce A. Reuter , 61
Sr. VP of International Sales, Marketing & Distribution |
$
254.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.52% Nasdaq 0.00%
Profile
